Clinical trial · Observational
A Pilot Study of the VosCryoTM Breathalyser in Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CryoPilot is a single-centre pilot study being conducted at Weston Park Cancer Centre in Sheffield, UK. The goal of this pilot study is to determine whether small-volume exhaled breath condensate sample (EBC) obtained via a VosCryo™ breath sample collection device can provide quantifiable and analysable cellular material, including epithelial cells, leukocytes, or exfoliated tumour cells, in patients with late-stage lung cancer. The main question it aims to answer is whether a breath sample can provide the necessary cellular information that could eventually be used for diagnostic purposes. The secondary objective is to compare the presence and quality of such material with that obtained from healthy relatives who will act as a low-risk control group, to assess whether EBC-based analysis may differentiate between cancerous and non-cancerous states. As such this pilot study will have two arms: * Experimental arm: 12 patients with late-stage lung cancer * Control arm: 12 low-risk relatives of patients with late-stage lung cancer Participants will be approached during their visit to Weston Park Hospital and asked to provide informed consent, followed by provision of a breath sample.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Expiratory Breath Condensate Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Experimental Arm
- description
- Patients with advanced/late-stage lung cancer
- interventionNames
- Other: Expiratory Breath Condensate Collection
- label
- Control Arm
- description
- Relatives of advanced lung cancer patients, at low risk of/with no known malignancy.
- interventionNames
- Other: Expiratory Breath Condensate Collection
Primary outcomes (1)
- measure
- Availability of Analysable Sample Material
- timeFrame
- At Collection of EBC Sample
- description
- The number of participants with lung cancer out of the total recruited to the experimental arm, who have analysable material within their exhaled breath condensate.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥16 years old * Ability to provide written informed consent * Either a history of advanced non-small cell or small cell lung cancer with intra-thoracic disease (pulmonary primary or pulmonary metastases), previously untreated by systemic anti-cancer treatment or radiotherapy * Patients with previously treated early-stage lung cancer are permitted * Patients with advanced disease with extra-thoracic disease previously treated by local therapy (e.g., palliative radiotherapy to a bone metastasis, or post brain metastectomy), which in the opinion of the Principal Investigator is unlikely to impact the quality of the EBC research sample are eligible * OR an attending relative or friend with no history of lung cancer or any other primary cancer, except for curatively treated non-melanomatous skin cancer or carcinoma in situ, unless the participant has been free of malignancy and off treatment for a period of at least 2 years prior to study enrolment * No intercurrent upper or lower respiratory tract infection * Able to complete the EBC sample collection Exclusion Criteria: * Participants with lung metastases from non-lung primary tumours * Participants unable to consent or unable to comply with the requirements for EBC sample collection
References
Publications (8)
- BACKGROUNDPhillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN. Detection of lung cancer with volatile markers in the breath. Chest. 2003 Jun;123(6):2115-23. doi: 10.1378/chest.123.6.2115. PMID 12796197
- BACKGROUNDPalomba L, Paris D, Tramice A, Ambrosino P, Maniscalco M, Motta A. Detection of Cells in Exhaled Breath Condensate Holds Potential for Pathophysiological Insights in Pulmonary Diseases. Am J Respir Cell Mol Biol. 2023 Jul;69(1):113-115. doi: 10.1165/rcmb.2023-0022LE. No abstract available. PMID 37387613
- BACKGROUNDMutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med. 2001 Sep 1;164(5):731-7. doi: 10.1164/ajrccm.164.5.2101032. No abstract available. PMID 11549524
- BACKGROUNDKharitonov SA, Barnes PJ. Exhaled biomarkers. Chest. 2006 Nov;130(5):1541-6. doi: 10.1378/chest.130.5.1541. PMID 17099035
- BACKGROUNDHorvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jobsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005 Sep;26(3):523-48. doi: 10.1183/09031936.05.00029705. PMID 16135737
- BACKGROUNDDepartment of Health and Social Care. (2017). UK Policy Framework for Health and Social Care Research. (accessed at https://www.hra.nhs.uk/planning-and-improving-research/policies-standards- legislation/uk-policy-framework-health-social-care-research/)
- BACKGROUNDCarpagnano GE, Foschino-Barbaro MP, Mule G, Resta O, Tommasi S, Mangia A, Carpagnano F, Stea G, Susca A, Di Gioia G, De Lena M, Paradiso A. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med. 2005 Sep 15;172(6):738-44. doi: 10.1164/rccm.200503-439OC. Epub 2005 Jun 9.